<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00839488</url>
  </required_header>
  <id_info>
    <org_study_id>FEMH-95-C-011</org_study_id>
    <nct_id>NCT00839488</nct_id>
  </id_info>
  <brief_title>Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis</brief_title>
  <official_title>Comparison of Intravenous Pantoprazole and Famotidine for Stress Ulcer Prophylaxis in Patients After Major Abdominal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Far Eastern Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Far Eastern Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although stress ulcer is a complication that can cause significant mortality and morbidity in
      critical patients with risk factors, there is still lack of consensus about its prophylaxis.
      There are also few data available from Taiwan. H2 blockers are commonly used due to
      convenience. Some prefer sucralfate (a mucosal protective agent) for the sake of less
      association with nosocomial pneumonia. Recently, proton pump inhibitors were shown to have
      good prophylactic effects for stress ulcer. Pantoprazole (iv) is the first intravenous form
      of proton pump inhibitor that was approved by FDA. There are some reports about its
      application for treatment of peptic ulcer bleeding. It also has good acid suppression effect
      in patients under critical care. We expect that intravenous pantoprazole will have a role in
      stress ulcer prophylaxis.

      We will enroll those patients that have received major abdominal surgery and admitted to
      surgical ICU. After obtaining the consent, we will give them prophylactic drugs for 7 days
      within 24 hours. They are randomly allocated to 2 groups. Group I: pantoprazole 40 mg iv
      bolus stat and then qd ; Group II: famotidine 20 mg iv bolus stat and then q12h. We will
      monitor the following data: operation type &amp; time, APACHE II score, CBC, CXR, stool character
      and OB test, NG aspirate. If clinical evidence of UGI bleeding occurs, endoscopic examination
      will be performed. We define the end point as overt bleeding, death or transfer out of ICU.
      We will compare the prevalence of UGI bleeding and ventilator associated pneumonia in these 2
      groups
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient selection: those receive major abdominal operation (estimated postopeartive ICU stay
      more than 7 days); agree and give their consent(by their surrogate)within 24 hours after
      admissionto SICU; those are less than 18 y/o, pregnant, history of allergy to esomeprazole or
      famotidine, already have GI bleding are excluded Randomized to 2 groups: (1) 1st group to
      receuve pantoprazole 40 mg iv bolus stat and then qd, (2)2nd group to receive famotidine 20
      mg iv bolus stat and then q12h;prophylactically used for 7 days; estimated enrollment of 60
      patients for each group Monitoring items: recording opeartion procedure and time; APACHE II
      score at baseline, CBC、CXR at basleine and qod, stool OB at baseline; NG
      drainage、sputum、stool character, ICU routine （TPR, BP）;ICU stay，mortality rate at 30 days;
      EGD perfomed according to decision of attending physician End points: apparant UGI
      bleeding（tarry stool, meatemesus, large amount(more than 60 ml) of coffee ground from
      NG、decrease of Hb more than 2g/dl and endoscopically proved lesion）, mortality; ventilator
      associated pneumonia: new and persistent hazziness in CXR &amp; examination of tracheal aspirate,
      judged by chest specialist
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    the chief of GS left the hopsital and the successor did't want to keep on this study
  </why_stopped>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>apparant upper gastrointestinal bleeding</measure>
    <time_frame>7 days, within the interval of drug prophylaxis</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>microscopic gastrointestinal bleeding, ventilator associated pneumonia</measure>
    <time_frame>7 days, within the interval of drug prophaxis</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Stomach Ulcer</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pantoprazole 40 mg iv qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>famotidine 20 mg q12h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pantoprazole 40 mg iv</intervention_name>
    <description>pnatoprazole 40 mg iv qd</description>
    <arm_group_label>I</arm_group_label>
    <other_name>Pantoloc iv</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>famotidine 20 mg iv</intervention_name>
    <description>famotidine 20 mg q12h</description>
    <arm_group_label>II</arm_group_label>
    <other_name>gaster iv</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  those recieved major abdominal surgery (estimated admission to sirgical ICU more than
             7 days); give written consent and was randomized within 24 hours of admission

        Exclusion Criteria:

          -  age less than 18 y/o; pregnant; allergy to famotidine or pantoprazole; have had GI
             bleeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tzong Hsi Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Far Eastern Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Far Eastern Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>22050</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Cook DJ, Fuller HD, Guyatt GH, Marshall JC, Leasa D, Hall R, Winton TL, Rutledge F, Todd TJ, Roy P, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med. 1994 Feb 10;330(6):377-81.</citation>
    <PMID>8284001</PMID>
  </reference>
  <reference>
    <citation>Maier RV, Mitchell D, Gentilello L. Optimal therapy for stress gastritis. Ann Surg. 1994 Sep;220(3):353-60; discussion 360-3.</citation>
    <PMID>8092901</PMID>
  </reference>
  <reference>
    <citation>Lu WY, Rhoney DH, Boling WB, Johnson JD, Smith TC. A review of stress ulcer prophylaxis in the neurosurgical intensive care unit. Neurosurgery. 1997 Aug;41(2):416-25; discussion 425-6. Review.</citation>
    <PMID>9257310</PMID>
  </reference>
  <reference>
    <citation>Lam NP, Lê PD, Crawford SY, Patel S. National survey of stress ulcer prophylaxis. Crit Care Med. 1999 Jan;27(1):98-103.</citation>
    <PMID>9934901</PMID>
  </reference>
  <reference>
    <citation>Cook DJ, Reeve BK, Guyatt GH, Heyland DK, Griffith LE, Buckingham L, Tryba M. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. JAMA. 1996 Jan 24-31;275(4):308-14.</citation>
    <PMID>8544272</PMID>
  </reference>
  <reference>
    <citation>Allen ME, Kopp BJ, Erstad BL. Stress ulcer prophylaxis in the postoperative period. Am J Health Syst Pharm. 2004 Mar 15;61(6):588-96. Review.</citation>
    <PMID>15061430</PMID>
  </reference>
  <reference>
    <citation>Kantorova I, Svoboda P, Scheer P, Doubek J, Rehorkova D, Bosakova H, Ochmann J. Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial. Hepatogastroenterology. 2004 May-Jun;51(57):757-61.</citation>
    <PMID>15143910</PMID>
  </reference>
  <reference>
    <citation>Tryba M, Cook D. Current guidelines on stress ulcer prophylaxis. Drugs. 1997 Oct;54(4):581-96. Review.</citation>
    <PMID>9339962</PMID>
  </reference>
  <reference>
    <citation>Martin LF, Booth FV, Karlstadt RG, Silverstein JH, Jacobs DM, Hampsey J, Bowman SC, D'Ambrosio CA, Rockhold FW. Continuous intravenous cimetidine decreases stress-related upper gastrointestinal hemorrhage without promoting pneumonia. Crit Care Med. 1993 Jan;21(1):19-30.</citation>
    <PMID>8420726</PMID>
  </reference>
  <reference>
    <citation>Driks MR, Craven DE, Celli BR, Manning M, Burke RA, Garvin GM, Kunches LM, Farber HW, Wedel SA, McCabe WR. Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers. The role of gastric colonization. N Engl J Med. 1987 Nov 26;317(22):1376-82.</citation>
    <PMID>2891032</PMID>
  </reference>
  <reference>
    <citation>Fabian TC, Boucher BA, Croce MA, Kuhl DA, Janning SW, Coffey BC, Kudsk KA. Pneumonia and stress ulceration in severely injured patients. A prospective evaluation of the effects of stress ulcer prophylaxis. Arch Surg. 1993 Feb;128(2):185-91; discussion 191-2.</citation>
    <PMID>8431119</PMID>
  </reference>
  <reference>
    <citation>Pal BK, Roy-Burman P. RNA tumor virus phosphoproteins: subvirion location of the multiple phosphorylated species. Virology. 1977 Dec;83(2):423-7.</citation>
    <PMID>201091</PMID>
  </reference>
  <reference>
    <citation>Lasky MR, Metzler MH, Phillips JO. A prospective study of omeprazole suspension to prevent clinically significant gastrointestinal bleeding from stress ulcers in mechanically ventilated trauma patients. J Trauma. 1998 Mar;44(3):527-33.</citation>
    <PMID>9529184</PMID>
  </reference>
  <reference>
    <citation>Huggins RM, Scates AC, Latour JK. Intravenous proton-pump inhibitors versus H2-antagonists for treatment of GI bleeding. Ann Pharmacother. 2003 Mar;37(3):433-7. Review.</citation>
    <PMID>12639176</PMID>
  </reference>
  <reference>
    <citation>Hsu PI, Lo GH, Lo CC, Lin CK, Chan HH, Wu CJ, Shie CB, Tsai PM, Wu DC, Wang WM, Lai KH. Intravenous pantoprazole versus ranitidine for prevention of rebleeding after endoscopic hemostasis of bleeding peptic ulcers. World J Gastroenterol. 2004 Dec 15;10(24):3666-9.</citation>
    <PMID>15534928</PMID>
  </reference>
  <reference>
    <citation>Trépanier EF. Intravenous pantoprazole: a new tool for acutely ill patients who require acid suppression. Can J Gastroenterol. 2000 Nov;14 Suppl D:11D-20D. Review.</citation>
    <PMID>11110607</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2009</study_first_submitted>
  <study_first_submitted_qc>February 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2009</study_first_posted>
  <last_update_submitted>October 12, 2013</last_update_submitted>
  <last_update_submitted_qc>October 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Far Eastern Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Tzong-Hsi Lee</investigator_full_name>
    <investigator_title>Chief of Division of Hepatology and Gastroenterology</investigator_title>
  </responsible_party>
  <keyword>pantoprazole</keyword>
  <keyword>famotidine</keyword>
  <keyword>stomach ulcer</keyword>
  <keyword>digestive system surgical procedure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Stomach Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pantoprazole</mesh_term>
    <mesh_term>Famotidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

